{"pmid":32418874,"title":"Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.","text":["Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.","In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care.","Heart Lung Circ","Gray, Belinda","Semsarian, Christopher","Fatkin, Diane","Ingles, Jodie","Atherton, John J","Davis, Andrew M","Sanders, Prashanthan","Pachter, Nicholas","Skinner, Jonathan R","Stiles, Martin K","32418874"],"abstract":["In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care."],"journal":"Heart Lung Circ","authors":["Gray, Belinda","Semsarian, Christopher","Fatkin, Diane","Ingles, Jodie","Atherton, John J","Davis, Andrew M","Sanders, Prashanthan","Pachter, Nicholas","Skinner, Jonathan R","Stiles, Martin K"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418874","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.hlc.2020.04.006","keywords":["brugada syndrome","covid-19","cardiomyopathy","catecholaminergic polymorphic ventricular tachycardia","genetic heart disease","long qt syndrome"],"locations":["Australia","New Zealand","Brugada","Australia","New Zealand"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1667159284503281664,"score":9.490897,"similar":[{"pmid":32244059,"pmcid":"PMC7156157","title":"SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.","text":["SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.","Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 virus and associated lung disease coronavirus disease 2019 (COVID-19) has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the effect on other diseases is also uncertain, especially inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic.","Heart Rhythm","Wu, Cheng-I","Postema, Pieter G","Arbelo, Elena","Behr, Elijah R","Bezzina, Connie R","Napolitano, Carlo","Robyns, Tomas","Probst, Vincent","Schulze-Bahr, Eric","Remme, Carol Ann","Wilde, Arthur A M","32244059"],"abstract":["Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 virus and associated lung disease coronavirus disease 2019 (COVID-19) has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the effect on other diseases is also uncertain, especially inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic."],"journal":"Heart Rhythm","authors":["Wu, Cheng-I","Postema, Pieter G","Arbelo, Elena","Behr, Elijah R","Bezzina, Connie R","Napolitano, Carlo","Robyns, Tomas","Probst, Vincent","Schulze-Bahr, Eric","Remme, Carol Ann","Wilde, Arthur A M"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32244059","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.hrthm.2020.03.024","keywords":["brugada syndrome","covid-19","catecholaminergic polymorphic ventricular tachycardia","long qt syndrome","sars-cov-2","short qt syndrome"],"locations":["Brugada"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138492117188608,"score":433.8692},{"pmid":32418875,"title":"COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).","text":["COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).","Up to one-third of COVID-19 patients admitted to intensive care develop an acute cardiomyopathy, which may represent myocarditis or stress cardiomyopathy. Further, while mortality in older patients with COVID-19 appears related to multi-organ failure complicating acute respiratory distress syndrome (ARDS), the cause of death in younger patients may be related to acute heart failure. Cardiac involvement needs to be considered early on in critically ill COVID-19 patients, and even after the acute respiratory phase is passing. This Statement presents a screening algorithm to better identify COVID-19 patients at risk for severe heart failure and circulatory collapse, while balancing the need to protect health care workers and preserve personal protective equipment (PPE). The significance of serum troponin levels and the role of telemetry and targeted transthoracic echocardiography (TTE) in patient investigation and management are addressed, as are fundamental considerations in the management of acute heart failure in COVID-19 patients.","Heart Lung Circ","Lal, Sean","Hayward, Christopher S","De Pasquale, Carmine","Kaye, David","Javorsky, George","Bergin, Peter","Atherton, John J","Ilton, Marcus K","Weintraub, Robert G","Nair, Priya","Rudas, Mate","Dembo, Lawrence","Doughty, Robert N","Kumarasinghe, Gayathri","Juergens, Craig","Bannon, Paul G","Bart, Nicole K","Chow, Clara K","Lattimore, Jo-Dee","Kritharides, Leonard","Totaro, Richard","Macdonald, Peter S","32418875"],"abstract":["Up to one-third of COVID-19 patients admitted to intensive care develop an acute cardiomyopathy, which may represent myocarditis or stress cardiomyopathy. Further, while mortality in older patients with COVID-19 appears related to multi-organ failure complicating acute respiratory distress syndrome (ARDS), the cause of death in younger patients may be related to acute heart failure. Cardiac involvement needs to be considered early on in critically ill COVID-19 patients, and even after the acute respiratory phase is passing. This Statement presents a screening algorithm to better identify COVID-19 patients at risk for severe heart failure and circulatory collapse, while balancing the need to protect health care workers and preserve personal protective equipment (PPE). The significance of serum troponin levels and the role of telemetry and targeted transthoracic echocardiography (TTE) in patient investigation and management are addressed, as are fundamental considerations in the management of acute heart failure in COVID-19 patients."],"journal":"Heart Lung Circ","authors":["Lal, Sean","Hayward, Christopher S","De Pasquale, Carmine","Kaye, David","Javorsky, George","Bergin, Peter","Atherton, John J","Ilton, Marcus K","Weintraub, Robert G","Nair, Priya","Rudas, Mate","Dembo, Lawrence","Doughty, Robert N","Kumarasinghe, Gayathri","Juergens, Craig","Bannon, Paul G","Bart, Nicole K","Chow, Clara K","Lattimore, Jo-Dee","Kritharides, Leonard","Totaro, Richard","Macdonald, Peter S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418875","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.hlc.2020.04.005","keywords":["acute cardiomyopathy","covid-19","high sensitivity troponin","myocarditis","screening algorithm","targeted transthoracic echocardiogram"],"locations":["New Zealand"],"countries":["New Zealand"],"countries_codes":["NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1667159284390035457,"score":231.08298},{"pmid":32415723,"title":"Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.","text":["Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.","The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.","Intern Med J","Di Ciaccio, Pietro","McCaughan, Georgia","Trotman, Judith","Ho, Phoebe Joy","Cheah, Chan Y","Gangatharan, Shane","Wight, Joel","Ku, Matthew","Quach, Hang","Gasiorowski, Robin","Polizzotto, Mark N","Prince, Henry Miles","Mulligan, Stephen","Tam, Constantine S","Gregory, Gareth","Hapgood, Greg","Spencer, Andrew","Dickinson, Michael","Latimer, Maya","Johnston, Anna","Armytage, Tasman","Lee, Cindy","Cochrane, Tara","Berkhahn, Leanne","Weinkove, Robert","Doocey, Richard","Harrison, Simon J","Webber, Nicholas","Lee, Hui-Peng","Chapman, Scott","Campbell, Belinda A","Gibbs, Simon D J","Hamad, Nada","32415723"],"abstract":["The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources."],"journal":"Intern Med J","authors":["Di Ciaccio, Pietro","McCaughan, Georgia","Trotman, Judith","Ho, Phoebe Joy","Cheah, Chan Y","Gangatharan, Shane","Wight, Joel","Ku, Matthew","Quach, Hang","Gasiorowski, Robin","Polizzotto, Mark N","Prince, Henry Miles","Mulligan, Stephen","Tam, Constantine S","Gregory, Gareth","Hapgood, Greg","Spencer, Andrew","Dickinson, Michael","Latimer, Maya","Johnston, Anna","Armytage, Tasman","Lee, Cindy","Cochrane, Tara","Berkhahn, Leanne","Weinkove, Robert","Doocey, Richard","Harrison, Simon J","Webber, Nicholas","Lee, Hui-Peng","Chapman, Scott","Campbell, Belinda A","Gibbs, Simon D J","Hamad, Nada"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415723","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/imj.14859","keywords":["covid-19","chronic lymphocytic leukaemia","lymphoma","myeloma"],"locations":["Australia","New Zealand","Australian","New Zealand","lymphoma"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1666991242696720384,"score":203.10825},{"pmid":32487432,"title":"Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.","text":["Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.","THE CHALLENGES: Rural and remote Australians and New Zealanders have a higher rate of adverse outcomes due to acute myocardial infarction, driven by many factors. The prevalence of cardiovascular disease (CVD) is also higher in regional and remote populations, and people with known CVD have increased morbidity and mortality from coronavirus disease 2019 (COVID-19). In addition, COVID-19 is associated with serious cardiac manifestations, potentially placing additional demand on limited regional services at a time of diminished visiting metropolitan support with restricted travel. Inter-hospital transfer is currently challenging as receiving centres enact pandemic protocols, creating potential delays, and cardiovascular resources are diverted to increasing intensive care unit (ICU) and emergency department (ED) capacity. Regional and rural centres have limited staff resources, placing cardiac services at risk in the event of staff infection or quarantine during the pandemic.","Heart Lung Circ","Arnold, Ruth H","Tideman, Philip A","Devlin, Gerard P","Carroll, Gerard E","Elder, Alex","Lowe, Harry","Macdonald, Peter S","Bannon, Paul G","Juergens, Craig","McGuire, Mark","Mariani, Justin A","Coffey, Sean","Faddy, Steven","Brown, Alex","Inglis, Sally","Wang, William Y S","32487432"],"abstract":["THE CHALLENGES: Rural and remote Australians and New Zealanders have a higher rate of adverse outcomes due to acute myocardial infarction, driven by many factors. The prevalence of cardiovascular disease (CVD) is also higher in regional and remote populations, and people with known CVD have increased morbidity and mortality from coronavirus disease 2019 (COVID-19). In addition, COVID-19 is associated with serious cardiac manifestations, potentially placing additional demand on limited regional services at a time of diminished visiting metropolitan support with restricted travel. Inter-hospital transfer is currently challenging as receiving centres enact pandemic protocols, creating potential delays, and cardiovascular resources are diverted to increasing intensive care unit (ICU) and emergency department (ED) capacity. Regional and rural centres have limited staff resources, placing cardiac services at risk in the event of staff infection or quarantine during the pandemic."],"journal":"Heart Lung Circ","authors":["Arnold, Ruth H","Tideman, Philip A","Devlin, Gerard P","Carroll, Gerard E","Elder, Alex","Lowe, Harry","Macdonald, Peter S","Bannon, Paul G","Juergens, Craig","McGuire, Mark","Mariani, Justin A","Coffey, Sean","Faddy, Steven","Brown, Alex","Inglis, Sally","Wang, William Y S"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32487432","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.hlc.2020.05.001","keywords":["covid-19","cardiac services","remote monitoring","rural","telehealth"],"locations":["Australians","New Zealanders","New Zealand"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1668623433492070400,"score":198.73502},{"pmid":32467031,"pmcid":"PMC7202319","title":"CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.","text":["CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.","This Cardiac Society of Australia and New Zealand (CSANZ) Imaging Council Position Statement aims to guide local, regional and national clinical practice, and facilitate resource and echocardiographic service planning appropriately during the current COVID-19 global pandemic. General considerations include workforce arrangements and contingency plans, patient risk assessment for COVID-19 and level of care (personal protective equipment) for staff. Both outpatient and inpatient settings are addressed, including specific considerations in the in-patient setting including scanning protocols, screening modalities and indications for echocardiograms in the context of COVID-19 infection.","Heart Lung Circ","Wahi, Sudhir","Thomas, Liza","Stanton, Tony","Taylor, Andrew","Mahadevan, Devan","Evans, Geoffrey","Playford, David","To, Andrew","Davis, Mark","Anderson, Bonita","Buckley, Belinda","32467031"],"abstract":["This Cardiac Society of Australia and New Zealand (CSANZ) Imaging Council Position Statement aims to guide local, regional and national clinical practice, and facilitate resource and echocardiographic service planning appropriately during the current COVID-19 global pandemic. General considerations include workforce arrangements and contingency plans, patient risk assessment for COVID-19 and level of care (personal protective equipment) for staff. Both outpatient and inpatient settings are addressed, including specific considerations in the in-patient setting including scanning protocols, screening modalities and indications for echocardiograms in the context of COVID-19 infection."],"journal":"Heart Lung Circ","authors":["Wahi, Sudhir","Thomas, Liza","Stanton, Tony","Taylor, Andrew","Mahadevan, Devan","Evans, Geoffrey","Playford, David","To, Andrew","Davis, Mark","Anderson, Bonita","Buckley, Belinda"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467031","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.hlc.2020.04.003","keywords":["covid-19","echocardiography","patient risk assessment","personal protective equipment"],"locations":["New Zealand"],"countries":["New Zealand"],"countries_codes":["NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1668420887166058496,"score":191.64992}]}